Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
Lijnen
H Roger
HR
D000273:Adipose Tissue / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D007783:Lactones / Q000494:pharmacology*; D020738:Leptin / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D013450:Sulfones / Q000494:pharmacology*
D019440:Anti-Obesity Agents; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D020738:Leptin; D013450:Sulfones; C116926:rofecoxib; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2